HAVCR2 and hepatocellular carcinoma: Several TIM-3 and LAG-3 agents are currently in clinical development, TIM3 monoclonal antibody TSR-022 (NCT03680508) and with a phase II study combined with anti-PD-1 antibody in HCC patients and mainly include INCAGN02385 (NCT03538028, monotherapy), Relatlimab (NCT04567615) and LAG-3 monoclonal antibody XmAb22841 (NCT03849469 combined with PD-1.